Sensei Biotherapeutics, Inc. (SNSE)
- Previous Close
1.0400 - Open
1.0200 - Bid 0.7272 x 200
- Ask 1.3300 x 200
- Day's Range
1.0090 - 1.0399 - 52 Week Range
0.5100 - 1.7200 - Volume
6,144 - Avg. Volume
71,896 - Market Cap (intraday)
25.572M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2200 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.67
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
www.senseibio.comRecent News: SNSE
Performance Overview: SNSE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNSE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNSE
Valuation Measures
Market Cap
25.07M
Enterprise Value
-34.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.97%
Return on Equity (ttm)
-40.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-34.1M
Diluted EPS (ttm)
-1.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
65.76M
Total Debt/Equity (mrq)
9.57%
Levered Free Cash Flow (ttm)
-21.32M
Research Analysis: SNSE
Company Insights: SNSE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SNSE
Daily – Vickers Top Insider Picks for 05/13/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/12/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/11/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/10/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.